EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials

Ibrahim Khalil iD, M Rafiqul Islam iD, Sunjida Amin Promi, Arindam Das Joy, Md Abu Sayed, Durjoy Acharjee, Ali Saad Al-Shammari iD, Sakib Abrar, Ta-Seen Bin Jamil, Malaika Taseen, Suborna Biswas, Sumaya Khan Mifty und 4 weitere

Clinical Cardiology · 2025

DOI: 10.1002/clc.70204 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Ibrahim Khalil und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dhaka Medical College and Hospital, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Cholesterol Ester Transfer Proteins, Hyperlipidemias, Anticholesteremic Agents, Lipids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperlipidemia, a key risk factor for cardiovascular disease, is characterized by elevated low‐density lipoprotein cholesterol (LDL‐C), triglycerides, and reduced high‐density lipoprotein cholesterol (HDL‐C). Cholesteryl ester transfer protein (CETP) inhibitors, such as anacetrapib, obicetrapib, evacetrapib, dalcetrapib, and torcetrapib, aim to improve lipid profiles by increasing HDL‐C and reducing LDL‐C, but their comparative efficacy remains unclear.

Methods

This systematic review and frequentist network meta‐analysis, conducted per PRISMA‐NMA guidelines, included 33 randomized controlled trials (RCTs) involving 120,292 adults with hyperlipidemia. We compared CETP inhibitors, alone or with statins, against placebo or other lipid‐lowering therapies. Primary outcome was LDL‐C reduction; secondary outcomes included HDL‐C, triglycerides, and total cholesterol changes. Random‐effects models calculated mean differences (MD) with 95% confidence intervals (CI), and P‐scores ranked interventions.

Results

Atorvastatin + obicetrapib showed the largest reduction in LDL‐C levels (MD: −69.00, 95% CI: −95.96 to −42.04, p < 0.0001), followed by rosuvastatin + obicetrapib (MD: −60.70, 95% CI: −99.28 to −22.12, p = 0.0020). Atorvastatin + obicetrapib yielded highly significant increase in HDL‐C levels (MD: 149.90, 95% CI: 121.70 to 178.10, p < 0.0001), but rosuvastatin + obicetrapib showed the greatest increase (MD: 158.90, 95% CI: 118.59 to 199.21, p < 0.0001) and obicetrapib monotherapy (MD: 139.00, 95% CI: 129.05 to 148.96, p < 0.0001), while rosuvastatin + evacetrapib led triglyceride reductions (MD: −31.70 mg/dL). Rosuvastatin was most effective for total cholesterol (MD: −31.60 mg/dL).

Conclusion

CETP inhibitors, particularly anacetrapib and obicetrapib combined with statins, significantly improve lipid profiles, offering potential therapeutic benefits for hyperlipidemia management and cardiovascular risk reduction. Trial Registration: The study was registered with PROSPERO to ensure transparency and adherence to methodological rigor (Registration ID: CRD420250652666).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol Ester Transfer ProteinsHyperlipidemiasAnticholesteremic AgentsLipidsHumansRandomized Controlled Trials as TopicAdultTreatment OutcomeBiomarkersCholesterol, HDLCholesterol, LDL

Stichwörter der Autor:innen

CETP inhibitorsanacetrapibhyperlipidemianetwork meta‐analysisobicetrapibstatins

Substanzen

Cholesterol Ester Transfer ProteinsAnticholesteremic AgentsLipidsCETP protein, humanBiomarkersCholesterol, HDLCholesterol, LDL

Autor:innen und Institutionen

  • Dhaka Medical College and Hospital, Dhaka, Bangladesh.
  • Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh.
  • Chattogram Medical College, Chattogram, Bangladesh.
  • College of Medicine, University of Baghdad, Baghdad, Iraq.
  • Gazi Medical College, Khulna, Bangladesh.
  • Jalalabad Ragib-Rabeya Medical College and Hospital, Sylhet, Bangladesh.

ORCID-Profile: Ibrahim Khalil, M Rafiqul Islam, Ali Saad Al-Shammari, Sajjad Ghanim Al-Badri

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Khalil, I., Islam, M. R., Promi, S. A., Joy, A. D., Sayed, M. A., Acharjee, D., Al-Shammari, A. S., Abrar, S., Jamil, T. B., Taseen, M., Biswas, S., Mifty, S. K., Al-Badri, S. G., Debnath, A., Hossain, M. I., & Akter, M. (2025). Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials. Clinical Cardiology. https://doi.org/10.1002/clc.70204

Vancouver

Khalil I, Islam MR, Promi SA, Joy AD, Sayed MA, Acharjee D, et al. Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials. Clinical Cardiology. 2025. doi:10.1002/clc.70204

BibTeX
@article{Khalil2025,
  author = {Khalil, Ibrahim and Islam, M Rafiqul and Promi, Sunjida Amin and Joy, Arindam Das and Sayed, Md Abu and Acharjee, Durjoy and Al-Shammari, Ali Saad and Abrar, Sakib and Jamil, Ta-Seen Bin and Taseen, Malaika and Biswas, Suborna and Mifty, Sumaya Khan and Al-Badri, Sajjad Ghanim and Debnath, Avijit and Hossain, Md Imran and Akter, Mahmuda},
  title = {Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials},
  journal = {Clinical Cardiology},
  year = {2025},
  doi = {10.1002/clc.70204}
}
Kostenlos starten →